Abstract-Apelin receptors, present on vascular smooth muscle cells, endothelium, and cardiomyocytes, are activated by the family of apelin peptides to elicit cardiovascular effects in experimental animals, but functional activity in humans has not been studied in detail. We detected low levels of apelin immunoreactivity in plasma of volunteers consistent with an autocrine/paracrine action and detected apelin immunoreactivity in the supernatant from human cultured endothelial cells. We found that [Pyr 1 ]apelin-13 was the predominant isoform in cardiac tissue from patients with coronary artery disease. We tested the hypothesis that apelins have vascular and cardiac actions in human tissues in vitro and compared responses to [Pyr 1 ]apelin-13, apelin-13, and apelin-36. In endothelium-intact mammary artery, all 3 of the apelins induced concentration-dependent vasodilatation with comparable potency (EC 50 : 0.6 to 1.6 nM; maximum response: 40% to 50%). Vasodilatation was abolished after endothelial removal or preincubation with indomethacin but was unaffected by preincubation with N G -nitro-L-arginine methyl ester, indicating involvement of prostanoids but not NO in dilatation by apelins in this patient group. Apelins were potent constrictors of endothelium-denuded saphenous vein (EC 50 : 0.6 to 1.6 nM; maximum response: 17% to 26%) and mammary artery ([Pyr 1 ]apelin-13; EC 50 : 0.2 nM; maximum response: 29%). In paced atrial strips, all 3 of the peptides increased the force of contraction with subnanomolar potencies (EC 50 : 40 to 125 pM). For the first time, we demonstrate that the 3 principal forms of apelin have comparable potency and efficacy in human cardiovascular tissues. Apelins are potent endothelium-dependent vasodilators acting via a prostanoid-dependent mechanism; however, removal of the endothelium revealed direct vasoconstrictor actions in both the artery and vein. Furthermore, in human cardiac tissue, the apelin peptides are among the most potent endogenous positive inotropic agents yet reported. A pelin peptides, derived from a single gene, activate the G protein-coupled receptor APJ that has high sequence similarity with the angiotensin II type 1 receptor but does not bind angiotensin II. 1,2 The precursor, preproapelin, 2-4 contains several proteolytic cleavage sites, 3 predicting formation of C-terminal peptides, including apelin-36, apelin-13, and [Pyr 1 ]apelin-13, 2,3,5 but the endogenous isoforms in humans remain to be identified. APJ modulates fluid homeostasis 4 -6 and acts as coreceptor for HIV infection, 7,8 and apelin is a novel adipokine 9 -11 with an emerging role in the cardiovascular system. 6,12-38 A role for apelin in human cardiovascular disease has been proposed; importantly, mRNA microarray analysis of Ͼ12 000 genes identified APJ as the most consistently and significantly increased gene in heart failure patients after mechanical offloading. 12 Circulating levels of apelin may be unchanged 13 or raised 12 in early stages of heart failure but were normalized 12 or decreased 14,15 in patients with severe disease.
A pelin peptides, derived from a single gene, activate the G protein-coupled receptor APJ that has high sequence similarity with the angiotensin II type 1 receptor but does not bind angiotensin II. 1, 2 The precursor, preproapelin, 2-4 contains several proteolytic cleavage sites, 3 predicting formation of C-terminal peptides, including apelin-36, apelin-13, and [Pyr 1 ]apelin-13, 2,3,5 but the endogenous isoforms in humans remain to be identified. APJ modulates fluid homeostasis 4 -6 and acts as coreceptor for HIV infection, 7, 8 and apelin is a novel adipokine 9 -11 with an emerging role in the cardiovascular system. 6, A role for apelin in human cardiovascular disease has been proposed; importantly, mRNA microarray analysis of Ͼ12 000 genes identified APJ as the most consistently and significantly increased gene in heart failure patients after mechanical offloading. 12 Circulating levels of apelin may be unchanged 13 or raised 12 in early stages of heart failure but were normalized 12 or decreased 14, 15 in patients with severe disease.
Apelin and APJ protein have been detected in endothelial cells of human arteries and veins, 16, 17 and apelin is a potent endothelial cell mitogen. 18 In healthy volunteers, [Pyr 1 ]apelin-13 and apelin-36 produced a rapid increase in forearm blood flow that was attenuated by NO synthase inhibition but unaffected by aspirin, implying a role for NO, 19 presumably released after activation of endothelial APJ. In rats, apelin lowered blood pressure, 4, 5, 20 and although APJ knockout mice displayed no change in blood pressure, the pressor response to angiotensin II was significantly increased. 21 The action of apelins in the vasculature of patients with cardiovascular disease has not yet been studied.
APJ receptors also localized to human and rat vascular smooth muscle, 17, 22 and we reported previously that [Pyr 1 ]apelin-13 constricted human saphenous vein. 22 We hypothesize that activation of smooth muscle APJ will produce vasoconstriction that is counterbalanced by dilatation, mediated by the endothelial APJ, 17 in a manner analogous to endothelin 1 (ET-1). 39 In the heart in vivo, apelin elicited inotropic actions in rodents [23] [24] [25] [26] thought to result from reflex sympathetic activation. 27 However, inotropic effects in a rat-isolated heart 17, 22 and localization of APJ in rat and human cardiomyocytes 17, 22 suggested a direct action. In agreement, deletion of the murine apelin gene resulted in an age-associated reduction in cardiac contractility. 29 No studies have yet reported the cardiac actions of apelins in humans.
Our aim was to identify apelin isoforms in human healthy and diseased cardiovascular tissues. We detected low levels in plasma from healthy volunteers and identified [Pyr 1 ]apelin-13 as the predominant isoform in cardiac tissues from patients with coronary artery disease. We determined the effect of apelin peptides on vascular tone in endothelium-denuded saphenous vein and mammary artery and whether they reversed ET-1-induced vasoconstriction in endothelium-intact artery. We further delineated the molecular mechanisms underlying endothelium-dependent vasodilator responses obtained with [Pyr 1 ]apelin-13 that we detected at highest levels in these patients. Finally, we sought evidence of a direct action of apelins on the human isolated paced atria.
[Pyr 1 ]apelin-13 has been identified previously as the most potent isoform in assays using cells expressing APJ, 2,3,30 -32 whereas apelin-36 was more effective in inhibiting HIV infection. 8, 33, 34 The rank order of potency of these peptides in native tissues has not been determined. Therefore, we compared the actions of [Pyr 1 ]apelin-13, apelin-13, and apelin-36.
Methods
All of the experiments described below were in accordance with institutional guidelines. This investigation conformed to the principles outlined in the Declaration of Helsinki. An expanded Methods section is available at http://hyper.ahajournals.org.
Cardiovascular Tissue Collection
All of the samples were obtained with local ethical approval and informed consent. Human mammary artery (nϭ46; age: 66.0Ϯ1.3 years), saphenous vein (nϭ43; age: 67.2Ϯ1.3 years), and atrial appendage (nϭ15; age: 59.9Ϯ3.0 years) were from patients receiving coronary artery bypass grafts, and plasma was from 5 healthy volunteers (age: 29.4Ϯ5.7 years). For patient information, see Table S1 in the online Data Supplement (available at http://hyper.ahajournals.org).
Cell Culture
Human umbilical vein endothelial cells were isolated by collagenase digestion, grown, and maintained in endothelial cell growth medium (EBM-2 bullet kit CC-3162; Lonza Wokingham Ltd, Berkshire, UK). Supernatant was collected from passages 1 to 3 and stored at Ϫ70°C.
Detection of Endogenous Apelin Peptides
Apelin levels were determined in the lyophilized atrial fractions and plasma and supernatant samples by radioimmunoassay.
In Vitro Functional Studies
Cumulative concentration-response curves were constructed for [
]apelin-13, apelin-13, and apelin-36 in endothelium-intact mammary artery preconstricted with ET-1 (10 nmol/L), endotheliumdenuded saphenous vein, and electrically paced atrial appendage strips.
Statistical Analyses
Measurements are meanϮSEM. Values of potency (pD 2 ) and maximum response (E MAX ) were determined using iterative curve-fitting software (FigP, Biosoft) and compared using 1-way ANOVA with Bonferroni t test posthoc analysis for multiple comparisons. A PϽ0.05 was considered statistically significant.
Results

Measurement of Apelin-Like Immunoreactivity and Identification of Apelin Isoforms
In plasma from healthy volunteers, we detected low levels of apelin-like immunoreactivity (0.147Ϯ0.011 pmol/L; nϭ5). These were below the level for detection of individual isoforms by high-performance liquid chromatography fractionation. However, radioimmunoassay detected a single peak of apelin-like immunoreactivity in the high-performance liquid chromatography-fractionated heart extract from patients with cardiovascular disease, corresponding with oxidized [Pyr 1 ]apelin-13 ( Figure 1A through 1D ; confirmed by mass spectrometry). Other isoforms were below the level for detection. We detected significant levels of apelin-like immunoreactivity in supernatant from human umbilical vein endothelial cells (0.12Ϯ0.03 pmol/L; nϭ10) compared with blank medium (Ͻ0.04 pmol/L; PϽ0.05).
Cardiac and Vascular Responses to Apelin Peptides
Baseline parameters are given in Table S2 ]apelin-13; Figure 2D ). In endothelium-intact artery, preincubation with N G -nitro-L-arginine methyl ester (300 mol/L) had no effect (pD 2 : 9.4Ϯ0.4; E MAX : 35Ϯ3%; nϭ4; Figure 2E ]apelin-13 vasodilator response (nϭ4; Figure 2F ). Control responses to prostacyclin in endothelium-denuded artery elicited a similar maximum response (53Ϯ14%; nϭ6) to [Pyr 1 ]apelin-13 (39Ϯ3%; PϾ0.05) in endothelium-intact artery ( Figure 3A ), and these were significantly less than that of diethylamine NONOate (115Ϯ7%; nϭ8; Figure 3B ). The control compound diethylamine (nϭ8) had no effect on responses to ET-1 ( Figure 3B ). Dilator responses to 1 mol/L of acetylcholine (41.1Ϯ8.5% reversal of 10 mol/L phenylephrine) were unaffected by N G -nitro-Larginine methyl ester (300 mol/L; 41.9Ϯ6.7%) but attenuated by indomethacin (5 mol/L; 17.6Ϯ8.2%; nϭ3). 
Constrictor Responses to Apelin Peptides in
Discussion
The predominant vascular effect of apelins in vivo reported in animals 4, 21 and in healthy human volunteers 19 is vasodilatation. This study describes for the first time the actions of 3 apelin peptides in cardiovascular preparations from patients with coronary artery disease. These are in agreement with previous reports of physiological roles of apelins in the vasculature 4, 5, 20, 35 and heart [23] [24] [25] of rodents and with the presence of apelin receptors in cardiomyocytes, vascular smooth muscle cells, and endothelial cells. 14, 17, 21, 22 It is not known which apelin isoforms have physiological or pathophysiological relevance. In rats, immunoreactive apelin was determined to be [Pyr 1 ]apelin-13, apelin-17, 41 or apelin-36. 31 An initial report in human tissues identified apelin species with molecular weight greater than that of apelin-36, 14 although, in a recent study, retention time of immunoreactive apelin was comparable with apelin-13. 13 In healthy volunteers we determined plasma apelin levels to be lower than expected for a circulating hormone and too low to identify the individual apelin isoforms. However, we found that, in cardiac tissue from patients, the predominant isoform was [Pyr 1 ]apelin-13, which may reflect the protection afforded by the modified pyroglu- tamate moiety. These data are consistent with our localization of apelin-like immunoreactivity to vascular and endocardial endothelial cells 16 in this tissue, indicating that apelins may act as locally released mediators, and, in support of this hypothesis, we detected apelin-like immunoreactivity in supernatants from human umbilical vein endothelial cells.
In the anesthetized rat in vivo, infused apelin elicited hypotension, resulting from the generation of NO. 20 In our experiments, the vasodilator response to the apelins in human mammary artery was endothelium dependent, like other vasoactive transmitters, 42 but mediated via release of cyclooxygenase products rather than NO. Cyclooxygenasemediated apelin signaling has been reported in the rat central nervous system. 43 Our observation may reflect species variation and may be specific to the vascular bed but most likely reflects endothelial dysfunction in arteries from patients with cardiovascular disease. This agrees with the only other report in human isolated blood vessels in which apelin-13-mediated vasodilatation in mesenteric artery from healthy individuals resulted from the release of NO, whereas NO was not involved in the relaxation of hepatic arteries from patients with liver cirrhosis. 36 In our study, all 3 of the apelins reversed ET-1 constriction by 40% to 50%, comparable with exogenous prostacyclin in endothelium-denuded artery. Thus, in conditions of endothelial dysfunction where vasoconstrictor tone to, eg, ET-1, is enhanced and NO production is attenuated, apelins have the potential to contribute to beneficial vasodilatation in an NO-independent manner.
Interestingly, in mammary artery, the removal of the endothelium unmasked vasoconstrictor responses for the apelins that we also observed in saphenous vein and that were comparable with responses to angiotensin II. Vascular peptides such as ET-1 elicit both vasodilatation and vasoconstriction; however, for apelins these opposing functions are mediated via the same receptor, albeit on different cell types (vascular endothelial cells and smooth muscle cells, respectively). Apelin-mediated phosphorylation of the myosin light chain kinase. 37 has been reported in vascular smooth muscle cells. Thus, in endothelium-intact blood vessels, endothelial APJ receptors may mediate vasodilatation as a counterregulatory mechanism limiting vasoconstriction induced by activation of APJ expressed on vascular smooth muscle. 42 Szokodi et al 25 demonstrated that apelin was as effective a positive inotropic agent in the rat heart, 25 as ET-1, 44 and as adrenomedullin, 45 and we find that the apelins are the most potent endogenous agents in human atria reported so far. 40, 46 Apelins have beneficial effects on cardiac performance in vivo in rats 24, 26 and mice, 23 and the increase in the cardiac force of contraction in vitro that we observed suggests that apelin may also have this potential in humans. Positive inotropic effects in vivo may be mediated via reflex sympathetic activation. 21 Our data are the first demonstration of direct effects of apelins on the force of contraction in human heart tissue and are consistent with apelin-increased sarcomere shortening in rat-isolated cardiomyocytes. 38 Variations in relative potencies of apelin peptides have been reported in cells expressing APJ. 2, 3, 31, 32 A key finding of our study is that, in all 3 of the preparations, the relative potencies of [Pyr 1 ]apelin-13, apelin-13, and apelin-36 were the same; therefore, we suggest that APJ activation in the human cardiovascular system will be comparable irrespective of the apelin isoform involved. This is not unexpected, because it has been shown that the 12 identical C-terminal amino acids shared by [Pyr 1 ]apelin-13, apelin-13, and apelin-36 comprise the biologically active core of these peptides. 5
Perspectives
Our data show that apelin peptides mediate 3 major actions in tissues from patients with cardiovascular disease: endothelium-dependent vasodilatation, direct vasoconstriction, and increased cardiac contractility. Vasodilatation is consistent with data from animals 4, 20, 21 and healthy volunteers. 19 However, where the endothelium is dysfunctional in disease, our studies suggest that, although the balance would be shifted toward vasoconstriction, some beneficial apelin-mediated vasodilatation persists that appears to be prostanoid depen- dent and NO independent. Data from apelin-infusion studies in patients is required to confirm this hypothesis. In support, the hypotensive response to apelin was observed but blunted in the spontaneously hypertensive rat compared with controls, 21 and the pressor response to angiotensin II was augmented in APJ knockout mice. 21 Blood pressures in the double angiotensin II type 1A and APJ knockout mice were raised compared with the angiotensin II type 1A knockout alone, 21 indicating that apelin vasodilatation counterbalances endogenous vasoconstrictor tone, at least in this species. In patients with chronic heart failure, plasma levels of apelin are unchanged or increased in early stages 12, 13 but then fall in more severe disease. 12, 14, 15 Our in vitro studies would suggest that this loss in apelin peptide would result in a concomitant reduction in beneficial positive inotropic apelin actions and would promote the deterioration of cardiovascular function. The development of selective APJ agonists and antagonists in the future will facilitate basic and integrative research toward unraveling the role of apelin peptides in the physiology and pathophysiology of the mammalian cardiovascular system. 
Methods
Cardiovascular Tissue Collection
Human left internal mammary artery (LIMA) (n=46; 37 male, 9 female, mean age 66.0±1.3 years), saphenous vein (n=43; 39 male, 4 female, mean age 67.2±1.3 years) and atrial appendage (n=15 male, mean age 59.9±3.0 years) were collected with local ethical approval and informed consent from patients undergoing coronary artery bypass graft surgery. For in vitro pharmacology, tissues were collected in Krebs solution and maintained at 4°C until use; for HPLC/radioimmunoassay atrial appendages were frozen and stored at -70ºC until used. See Table S1 for patient information. Blood was obtained with local ethical approval and informed consent from 5 healthy volunteers (2 male, 3 female, mean age 29.4±5.7 years).
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated by collagenase digestion, grown and maintained in endothelial cell growth media (EBM-2 bullet kit CC-3162). Cell culture supernatant was collected from passage 1-3 into EDTA coated tubes and stored at -70ºC.
Detection of Apelin Levels and Isoforms by Radioimmunoassay and HPLC
Extraction of Human Atrial Tissue, Plasma and HUVEC Supernatants
Plasma from 5 individuals, atria from 8 individuals and HUVEC supernatant from 10 cultures were prepared for solid phase extraction. as described for ET-1.
1 Blood samples from 5 healthy volunteers were collected into tubes containing EDTA. Samples were centrifuged at 2,000g for 10 minutes, 4ºC and plasma removed into polypropylene tubes. Atrial tissue samples (1-2g) from 8 individuals (see Table S1 ), devoid of fat, were cut into small pieces and homogenized using a Polytron PT.K homogenizer fitted with a PTA10S probe (Philip Harris Scientific, Hull, UK) in 10mL/g tissue of 0.5mol/L acetic acid. The homogenate was heated to 100°C for 15 minutes, cooled and centrifuged at 48000g for 1h, at 4 °C. The resulting tissue supernatant, plasma and HUVEC supernatant samples were acidified with an equal volume of 0.1 % trifluoroacetic acid (TFA) and the plasma and HUVEC supernatant were spun at 2000g for 10 minutes to remove precipitation. All samples were solid phase extracted using SEP-Pac Vac C18 cartridges containing 500mg of C18 and a vacuum manifold apparatus. The cartridges were conditioned with 2mL 80% methanol/0.1% TFA and washed with 9mL 0.1% TFA. Samples were loaded onto the columns and allowed to pass through under gravity. After washing with 12mL 0.1% TFA the peptides were eluted with 4mL 80% methanol/0.1% TFA. Eluates were evaporated to dryness using a centrifugal concentrator (Savant Speedvac; Life Sciences International Ltd., Basingstoke, UK) and stored at -70°C. The percentage recovery of peptide from plasma following solid phase extraction, determined using a sample of human atrial appendage spiked with apelin-36 (25pg) was 87%. HPLC analysis Separations were carried out on a C18 (250×4.60mm) column (Phenomenex, Macclesfield, UK) using a Gilson 305 binary gradient HPLC system. Flow rate was 1mL/min and 1mL fractions were collected using a LKB Helirac fraction collector (Pharmacia LKB, St Albans, Herts, UK). The gradient was selected using 5μmol/L injection of apelin peptides and online UV detection (Gilson 151 UV/Vis 210 nm). The optimized gradient selected was 20% to 24% acetonitrile with 0.1% trifluoroacetic acid and 0.1% triethylamine over 30 minutes. Following washing and a blank run, the system was standardized with 10nmol/L injections of apelin peptides, [Pyr 1 ]apelin-13, apelin-13 and apelin-36. Lyophilized atrial appendage extracts were reconstituted with deionized water and subjected to the same gradient. Standards and samples, collected as 1mL fractions, were evaporated to dryness and stored at -70°C.
Radioimmunoassay
The lyophilized fractionated atrial tissue and apelin standards, plasma and HUVEC supernatant samples together with rabbit anti-apelin-36 serum (Phoenix Pharmaceuticals, Belmont, CA, USA) were reconstituted in assay buffer (50mmol/L sodium phosphate, 0.05 % Tween 20, 8mmol/L sodium azide, pH 7.4). The biological samples, HPLC fractionated apelin peptides standards and apelin-36 RIA standards (Phoenix Pharmaceuticals, Belmont, CA, USA) (100μL samples, appropriately diluted in assay buffer) were incubated with 100μL of rabbit anti-apelin-36 serum for 16-24 hours at 4 °C. ]apelin-13 in the pellet was detected using a Cobra 5003 gamma counter (Canberra Packard, Pangbourne, Berks, UK). The standards curves were constructed to apelin-36 (10-1289pg/mL). The linear portion of the curve was in the range 15-150pg/mL and IC 50 values (the concentration of standard peptide that reduces the binding of the radioligand by 50%) ranged from 54 to 122pg/mL. The sensitivity of detection was defined as the amount of standard peptide required to reduce B 0 by 2 standard deviations (B 0 is equivalent to 100% [
]-apelin-13 bound) and was 12pg/mL. The intra-and inter-assay coefficients of variation (SD/mean) (expressed as a percentage) were calculated using a sample of human left ventricle from one individual. The intra-assay coefficient of variation (including variation owing to the solid phase extraction procedure) was 14.1% (6 determinations); the intra-assay coefficient of variation (excluding extraction variation, i.e. assay only) was 8.3% (3 determinations). The inter-assay coefficient of variation was 12.3% over 5 experiments. Cross-reactivity was obtained with [Pyr 1 ]apelin-13 (44%) and apelin-13 (40%)and with the RIA apelin-36 standard (100%). Structurally unrelated peptides (e.g. angiotensin-II, angiotensin-III, angiotensin-IV, ghrelin, endothelin-1, bradykinin, motilin, substance P and atrial natriuretic peptide) showed negligible crossreactivity in this assay. We did not detect apelin-like immunoreactivity in the fractions of atrial samples that coincided with the retention time for apelin-36 on the HPLC column (29 min). For confirmation, the presence of apelin-like immunoreactivity in these fractions was also looked for using an additional apelin assay (apelin-12 EIA kit, EK057-23, Phoenix Pharmaceuticals, Belmont, CA, USA) that showed no significant presence of endogenous apelin-36 in our sample. Mass Spectrometry ESI ms/ms analysis of HPLC fractions was carried out by Dr. L Packman (PNAC Facility, Dept. Biochemistry, University of Cambridge). Samples were desalted using C18 ziptip and eluted with 70% MeOH/0.2% formic acid. Samples were analysed on a Thermo Finnigan LCQ Classic ion-trap mass spectrometer using a static nanospray interface held at 0.7kV. Tandem ms/ms data was collected manually for target ions. Fragmentation spectra were interpreted manually and also forwarded as .dta files to Mascot search engine (www.matrixscience.com) for comparison against the NCBInr database. 2 and mounted in 5mL baths containing oxygenated Krebs solution for the measurement of isometric force development. Optimum resting tension was determined by repeated application of 0.1mol/L KCl at increasing levels of basal tension until no further increase in developed isometric force was obtained. After a 1h equilibration period, artery rings were pre-constricted with phenylephrine (1µmol/L) and tested for the presence, or successful removal, of functional endothelium using acetylcholine (1µmol/L). Those arteries showing a response to acetylcholine of <80% reversal of the phenylephrine response were not used in subsequent endothelium-dependent studies. A response of <10% reversal of the phenylephrine response by acetylcholine was required for arterial rings to be included in the endothelium-denuded studies. Arterial rings were washed and then preconstricted with ET-1 (10nmol/L) (Peptide Institute, Osaka, Japan), a peptide that produces sustained vasoconstriction and is known to contribute to the maintenance of vascular tone.
3 Cumulative concentration-response curves were constructed to [Pyr 1 ]apelin-13, apelin-13 and apelin-36 (10pmol/L-300nmol/L) (Peptide Institute, Osaka, Japan , Phoenix Pharmaceuticals, Belmont, CA, USA) in the pre-constricted endothelium-intact and denuded arterial rings with additional control experiments carried out in denuded arterial rings only to prostacyclin (0.1nmol/L-300nmol/L), the nitric oxide donor diethylamine NONOate (DEA/NO, Alexis Biochemicals, Nottinghamshire, UK) with diethylamine (DEA) (Alexis Biochemicals, Nottinghamshire, UK) used as a negative control; both DEA/NO and DEA used at 10nmol/L-30μmol/L. Experiments were terminated by addition of atrial natriuretic peptide (ANP, 10nmol/L) followed by S-nitroso-N-acetylpenicillamine (SNAP, 10μmol/L) to determine maximal receptor mediated and receptor-independent vasodilatation. Adjacent ET-1 preconstricted rings, to which no apelin peptides were added, served as time-matched controls. To investigate the mechanisms involved in any endothelium-dependent responses observed with the predominant endogenous apelin isoform, concentration-response curves were repeated to [Pyr 1 ]apelin-13 in endothelium-intact rings pre-incubated with the nitric oxide synthase inhibitor N G -nitro-L-arginine-methyl ester (L-NAME, 300μmol/L) or the nonselective cyclo-oxygenase inhibitor indomethacin (5μmol/L). Vasodilator responses were expressed as percentage reversal of the ET-1 constriction and the negative logarithm of the EC 50 value (pD 2 ) and the maximum response (E MAX ) were determined using iterative curve fitting software (FigP, Biosoft, Cambs, UK).
Vascular Constrictor Experiments
Rings (4mm) of histologically normal saphenous vein and LIMA were mechanically denuded of their endothelium and mounted in 5mL baths containing oxygenated Krebs solution for the measurement of isometric force development as described previously 4 and above. In saphenous vein rings at optimized resting tension, cumulative concentration-response curves were constructed to [Pyr 1 ]apelin-13, apelin-13 and apelin-36 (10pmol/L -100nmol/L). Cumulative concentration-response curves were constructed to the established vasoconstrictors phenylephrine (1nmol/L-100μmol/L) and angiotensin-II (10pmol/L100nmol/L) as controls. Experiments were terminated by addition of ET-1 (10nmol/L, Peptide Institute Inc., Osaka, Japan) followed by KCl (0.1mol/L) to determine maximal receptor mediated and receptor-independent vasoconstriction. Adjacent rings, to which apelin peptides were not added, served as time-matched controls. In additional experiments the predominant endogenous apelin isoform that we detected in cardiac tissue from this patient group, [Pyr 1 ]apelin-13, was tested for its ability to constrict endothelium-denuded mammary artery (4mm rings). Vasoconstrictor responses were expressed as a percentage of KCl induced vasoconstriction and data analyzed, as above, to determine values of pD 2 and E MAX .
Cardiac Functional Studies
Human atrial appendage (n=8) were cut into 3-4 mm strips, parallel to atrial trabecular muscle bundles and set up in 10mL organ baths containing oxygenated Krebs solution for isometric tension recordings as previously described. 5 After a 1h equilibration period, atrial strips were paced using field stimulation (1Hz square-wave pulse of 5ms duration, voltage just above threshold (<4.0V)). Basal tension was incrementally raised until no further increase in force response was observed. Atrial strips were adjusted to 50% of this tension and left to equilibrate for 30 minutes. Cumulative concentration-response curves were constructed for [Pyr 1 ]apelin-13, apelin-13 and apelin-36 (10pmol/L-10nmol/L) and endothelin-1 (ET-1, Peptide Institute Inc., Osaka, Japan) and experiments were terminated by addition of isoprenaline (0.2mmol/L), followed by CaCl 2 (6.7mmol/L), to determine maximal β 1 -adrenoceptor-mediated and external Ca 2+ -mediated increase in force of contraction. Inotropic effects of the apelin peptides were expressed as percentage of the maximum increase in force of contraction for CaCl2 and data analysed to determine values of pD 2 and E MAX as described above.
Statistical Analyses
Measurements were expressed as mean ± standard error of the mean (SEM). Vasodilator responses are expressed as percentage reversal of the pre-constriction to 10nmol/L ET-1 and vasoconstrictor responses expressed as a percentage of the terminal response to 0.1mol/L KCl. Basal parameters are given in Table S2 . Values of potency, expressed as the negative logarithm of the agonist concentration producing 50% of the maximum response (pD 2 ), and the maximum response (E max ) were determined using iterative curve fitting software (FigP, Biosoft, Cambs, UK).
Values of E max , and pD 2 for the three apelin peptides were compared using one way analysis of variance (ANOVA) in combination with Bonferroni's t-test post hoc analysis for multiple comparisons. A P value <0.05 was considered statistically significant.
Materials
ET-1 (Peptide Institute Inc., Osaka, Japan) stock solutions (0.1 mmol/L) were prepared in 0.1% acetic acid and stored at -20°C. [Pyr 1 ]apelin-13, apelin-13 and apelin-36 were from the Peptide Institute, Osaka, Japan, Bachem, St Helens, UK or Phoenix Pharmaceuticals, Belmont, CA, USA, and were prepared as 1mmol/L stock solutions in water and stored at -20ºC. Diethylamine NONOate and diethylamine (Alexis Biochemicals, Nottinghamshire, UK) were stored under nitrogen at -70°C and dissolved in 0.01M NaOH immediately prior to experiments. Prostacyclin (PGI 2 ) (Sigma-Aldrich Ltd., Dorset, UK) was prepared as a stock solution (1mM) in distilled water and stored in the dark at 4°C. All other reagents were from Sigma-Aldrich Ltd. (Dorset, UK) unless stated. Krebs solution (mmol/L: NaCl, 90; NaHCO 3 , 45; KCl, 5; MgSO 4 .7H 2 O, 0.5; Na 2 HPO 4 .2H 2 O, 1; CaCl 2 , 2.25; fumaric acid, 5; glutamic acid, 5; glucose, 10; sodium pyruvate, 5; pH 7.4; gassed with 95% O 2 /5% CO 2 , maintained at 37°C). 
